,7,8 In this study, ARV-825 (ARV) was selected as specific BRD4-targeted PROTAC to achieve target degradation and downregulation of BRD4 protein following subsequent suppression of c-Myc levels in VEM-resistant melanoma.9 Here, MYC is linked to melanoma.